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Objective: In coronary artery disease (CAD), concomitant peripheral arterial disease (PAD) entails increased systemic
inflammatory profile and more severe coronary atherosclerosis. We investigated the relationship between the inflamma-
tory status in the affected limb and CAD severity.
Methods: In 46 CADPAD and 31 CAD-alone patients, the inflammatory status of the leg circulation was measured by
the transfemoral gradients of neutrophil myeloperoxidase (MPOx) content and interleukin-6 (IL-6). CAD severity was
defined by evaluating coronary artery endothelial function, number of significant coronary stenoses, and prevalence of
three-vessel CAD and myocardial infarction (MI).
Results: In the affected limb of CADPAD patients, the transfemoral gradients of neutrophil MPOx content and IL-6
were higher (P < .01, for both) than in the healthy leg of CAD-only patients. At multivariate analysis, CADPAD
patients with transfemoral gradients of MPOx and IL-6 >median had a more compromised coronary artery endothelial
function (P < .05, for both). Furthermore, CADPAD patients with transfemoral gradients of neutrophil MPOx
content > median showed an independent association with a greater number of significant coronary stenoses, and a
greater prevalence of three-vessel CAD and previous MI (P < .01, for all). A more severe coronary atherosclerosis was
observed also in CADPAD patients with transfemoral gradients of IL-6 > median vs those with IL-6 < median,
although differences were not statistically significant.
Conclusion: In CAD patients, the coexistence of PAD does not necessarily entail a more severe coronary atherosclerosis.
Only those with an inflammatory status of the affected limb presents more severe CAD. Future studies will clarify whether
the presence of peripheral inflammation plays a mechanistic role in CAD evolution. (J Vasc Surg 2009;49:1465-71.)In patients with coronary artery disease (CAD), a coex-
istent peripheral arterial disease (PAD) entails a higher
mortality risk.1-4 This could reflect the finding that coro-
nary atherosclerosis is more severe in CADPAD than in
CAD-alone patients.5-7 Indeed, apart from being older,
CAD patients with PAD have a higher prevalence of diabe-
tes mellitus and hypertension than those without PAD,3-6
but the greater atherosclerotic coronary artery burden ap-
pears to be unrelated to classic risk factors.5,6 Thus, other
mechanisms may be involved. We have recently reported
that in CADPAD patients increased gradients of neutro-
phil myeloperoxidase (MPOx) content and interleukin-6
(IL-6) across the femoral circulation of the affected limb are
strongly associated with impaired coronary artery endothelial
function.8 Furthermore, serum from the claudicant limb
of CADPAD patients induced, in vitro, a significantly
greater release of monocyte chemoattractant protein-1
(MCP-1) from human coronary artery endothelial cells
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The difference disappeared when HCAECs were incubated
with serum from CAD-alone patients. Collectively, these
findings suggest that in PAD circulatory triggers originated
from the affected limb could activate the endothelium at
distant sites. Given the atherogenic potential of endothelial
dysfunction, the present study was designed to determine
whether there is a relationship between the degree of
peripheral arterial inflammation and the severity of CAD.
MATERIALS AND METHODS
Patients. In addition to the 40 patients included in the
original paper,8 we studied 37 more subjects admitted to
our department for elective coronary angiography because
the evidence of inducible myocardial ischemia during stress
tests. Therefore, the present study includes 46 PADCAD
and 31 CAD-alone patients. PADCAD patients had an
ankle-brachial index (ABI) 0.90 and referred a history of
intermittent claudication lasting at least 1 year. None had
critical limb ischemia. In CAD-alone patients, PAD was
excluded on the basis of echo-color-Doppler examination
and ABI 0.90. Patients with ABI 1.4 were excluded.
Other exclusion criteria were: a history of trauma, surgery,
or myocardial infarction (MI) in the previous 3 months, a
previous coronary or peripheral artery revascularization
procedure, unstable angina, malignant disease, acute and
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other pathologic condition associated with inflammation.
No patient was taking anti-inflammatory drugs other than
aspirin as an antiplatelet agent. All drugs were discontinued
for 18 hours or longer before the study, which was per-
formed in the morning after an overnight fast. All patients
gave their informed written consent to the protocol which
was approved by the Ethics Committee of our institution.
Methods. In each patient, clinical history and risk
factors were assessed. Smokers included current and former
smokers. Hypertension was diagnosed if systolic arterial
pressure exceeded 140 mm Hg and/or diastolic arterial
pressure exceeded 90 mm Hg, or if the patient used anti-
hypertensive drugs. Hypercholesterolemia was diagnosed if
plasma total cholesterol exceeded 240 mg/dL or plasma
low-density lipoprotein (LDL) cholesterol exceeded 130
mg/dL or if the patient used lipid-lowering drugs because
of a history of hypercholesterolemia. Diabetes mellitus was
diagnosed if plasma fasting glucose exceeded 126 mg/dL
or if the patient used hypoglycemic agents.
To assess the inflammatory status of the affected limb,
before angiography all subjects underwent simultaneous
blood sampling from the femoral vein (in the case of
CADPAD the femoral vein was that of the claudicant
limb), aorta, coronary sinus, and an antecubital vein for the
measurement of neutrophil MPOx content, and plasma
levels of IL-6 and high sensitivity (hs) C-reactive protein
(CRP). The neutrophil MPOx content was determined by
a Bayer H*1 analyzer (Bayer Diagnostic Division, Tarry-
town, NY) which calculates an MPOx index of the mean
neutrophilMPOx content as described elsewhere.9 Positive
values represent MPOx-rich neutrophils, and negative val-
ues represent neutrophils depleted ofMPOx consequent to
neutrophil activation. Thus, a lower MPOx index in blood
from the femoral vein, as compared with the aorta, repre-
sented an index of neutrophil activation through the fem-
oral vascular bed. Plasma levels of IL-6 were measured by a
high-sensitive ELISA method (Dade Behring Diagnostics,
Deerfield, Ill). CRP was determined using an hs assay
(Dade Behring Diagnostics).
To assess CAD severity we measured: (1) the endothe-
lial function of the epicardial arteries by evaluating their
vasomotor response to the cold pressor test (CPT); (2) the
number of stenosis 50% in the major coronary arteries;
(3) the prevalence of three-vessel CAD; and (4) the preva-
lence of previous MI.
Coronary artery endothelial function was measured as
follows. After a baseline left coronary angiogram, the pa-
tient immersed the right hand in iced water for 90 seconds
and a second coronary angiogram was recorded to evaluate
the coronary artery endothelial vasoreactivity to the CPT.
In each patient, an average of 3.2 segments were selected in
one projection on the baseline angiogram. The left anterior
descending coronary artery was used as the experimental
artery. Three coronary segments were considered: proximal
(from the ostium to first septal branch), mid (from the first
to second septal branch), and distal (after the second septalbranch). The presence of coronary stenosis was defined as
the percentage of diameter stenosis above 50. In stenotic
coronary arteries, whenever possible, at least one segment
proximal and one segment distal to the stenosis were ob-
tained. In case of ostial stenosis, two or more segments
distal to the stenosis were obtained. The luminal diameter
(LD) wasmeasured at end diastole by quantitative coronary
angiography using the catheter as a scaling device. In case
of stenotic coronary arteries, changes in LD of the stenosis
itself were analyzed separately from the changes of the
adjacent reference segments. The data from the stenotic
and adjacent reference segments were pooled because there
was a uniform response to the CPT. Data are presented as
average of % LD changes of coronary segments after CPT
compared to baseline.
To ensure proper filling of the coronaries with contrast
medium, an angioplasty guide catheter was used in each
case and an automated contrast delivery system was used to
inject the same contrast volume at the various steps of the
experimental protocol (Acist Medical Systems, Eden Prai-
rie, Minn). The identical projection was used for the anal-
ysis of the same segments at the different stages of the
protocol. Angiograms were recorded at 25 frames/second.
Heart rate and blood pressures were recorded during the
entire study protocol. The contrast medium used was the
nonionic monomer, hypo-osmolar (Iomeron 400, Bracco,
Italy).
Noteworthy, in the first 40 patients of our series (22
CADPAD and 18 CAD-alone) the relationship between
inflammation of the affected limb and coronary artery
endothelial function has been previously reported.8 In the
present paper, we doubled the CADPAD population,
increased the CAD-alone group and, in addition to evalu-
ate coronary artery endothelial function, we investigated
other measures of CAD severity in the entire population.
Statistical analysis. Inflammatory parameters and
continuous variables of CAD severity (number of signifi-
cant coronary artery stenoses and coronary artery endothe-
lial function), which were not normally distributed, were
expressed as median and interquartile range and analyzed
by non parametric tests. The Friedman test and the Wil-
coxon test were used for intra-group comparisons, and the
Kruskal-Wallis and the Mann-Whitney U tests for inter-
group comparisons. Categorical variables were compared
by 2 test. Correlations were tested with the Spearman
method. Multivariate regression analyses adjusted for age,
gender, smoke, hypercholesterolemia, hypertension, and
diabetes mellitus were used to assess the association of the
extent of inflammation in the affected limb with the mea-
sures of CAD severity as dependent variables. In particular,
linear logistic regression analysis was used when the depen-
dent variable was continuous (coronary artery endothelial
function and number of significant coronary stenoses),
while binary logistic analysis when the dependent variable
was categorical (prevalence of three-vessel CAD and previ-
ous MI).
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Table I shows the characteristics of the study popula-
tion.
Peripheral vascular inflammation. As Table II shows,
there was a significant transfemoral decrease in the MPOx
index in the affected limb of CADPAD patients. Actually,
median neutrophil MPOx content was 2.7 (range 4.8
to 1.4) in the aorta and 4.3 (range 7.0 to 1.0) in the
femoral vein (P  .01). Conversely, the neutrophil MPOx
content in aortic blood was similar to that in the coronary
sinus and in the antecubital vein. Therefore, as Fig 1 shows,
the venous-arterial (V-A) difference in MPOx content
across the femoral circulation (median 1.6 [range 2.9
to 0.2]) was significantly greater than that across the
coronary (median 0.0 [range 1.6 to 1.2], P  .01) and
the upper limb circulation (median 0.4 [range 1.3 to
0.2], P .01). Furthermore, the change in MPOx content
in the transfemoral circulation of affected legs was signifi-
cantly greater than that in the transfemoral circulation of
the healthy legs of CAD patients without PAD (median
0.1 [range0.2 to 0.4], P .01). In the latter group, the
MPOx content in the aorta was similar to that in the other
vascular districts (Table II).
Also plasma levels of IL-6 were higher in femoral
venous blood than in aortic blood (Table II). Differentially,
IL-6 levels in venous blood from the coronary sinus and
antecubital vein did not differ from those in aortic blood
(Table II). Thus, as Fig 1 shows, the IL-6 V-A difference
across the femoral circulation (median 0.18 [range 0.0 to
0.43] pg/mL) was greater than that across both coronary
(median 0.0 [range 0.2 to 0.1] pg/mL, P  .01) and
upper limb circulation (median 0.1 [range 0.3 to 0.1]
pg/mL, P  .01). It was also greater than that across the
femoral circulation of the legs of CAD-only patients (me-
dian 0.0 [range 0.2 to 0.1] pg/mL, P  .01).
Contrary to what was observed forMPOx and IL-6, the
Table I. Patients’ characteristics
CADPAD
(n  46)
CAD
(n  31) P value
Age (year) 63.0  8.5 64.2  5.7 .59
Gender (males) 38 (83) 24 (77) .57
Hypertension (%) 31 (67) 23 (74) .53
Hypercholesterolemia (%) 34 (74) 25 (81) .49
Diabetes mellitus (%) 12 (26) 7 (23) .73
Smoking (%) 40 (87) 23 (74) .15
ABI 0.62  0.10 1.13  0.10 .01
Previous MI 25 (54%) 12 (39%) .18
Treatments
Antiplatelets (%) 40 (87) 26 (84) .70
Statins (%) 31 (77) 21 (74) .97
ACE-inhibitor (%) 22 (48) 15 (48) .96
Beta-blockers (%) 8 (17) 7 (23) .53
Calcium-antagonists (%) 13 (28) 12 (39) .34
Nitrates (%) 11 (24) 9 (29) .61
CAD, Coronary artery disease; PAD, peripheral arterial disease; ABI, ankle-
brachial index; MI, myocardial infarction; ACE, angiotensin converting
enzyme.venous arterial difference in hs-CRP across the femoralcirculation of the affected limb was similar to that of the
other vascular districts (Table II).
In CADPAD patients, there was no relationship be-
tween the ABI and the transfemoral V-A differences of
plasma levels of IL-6 (P  .13), neutrophil MPOx con-
tent (P  .07) and CRP (P  .24).
Peripheral vascular inflammation and coronary ar-
tery endothelial function. Coronary artery endothelial
function tended to be lower in CADPAD than in CAD-
alone patients (median 0.0 [range 1.8 to 2.0] vs 3.0
[3.0; 6.0] %; P .16). As shown in Fig 2, coronary artery
endothelial function progressively decreased from CAD-
alone patients (median 3.0 [range3.0 to 6.0] %), CAD
PAD patients with transfemoral gradient of MPOx  me-
dian (median 1.0 [range 1.0 to 11.0] %) to CADPAD
patients with transfemoral gradient of MPOx  median
(median 1.8 [range 10.6 to 1.0] %) (P for trend 
.01). The corresponding values for IL-6 were 3.0 (range
3.0 to 6.0) %, 2.0 (range1.0 to 6.0) %, and2.0 (range
13.8 to 0.5) % (P for trend  .05) (Fig 3). At Mann-
Whitney U test, coronary artery endothelial function was
significantly more compromised in CADPAD patients
with transfemoral gradients of both MPOx and IL-6 
median than in the other two groups (Figs 2 and 3).
Conversely, coronary artery endothelial function was simi-
lar in CADPAD patients categorized according to the
median value of transfemoral gradient of CRP and in
CAD-alone patients (data not shown).
In CADPAD, coronary artery endothelial function
correlated with transfemoral (V-A) difference of leukocyte
MPOx content (P  .65, P  .01) and IL-6 plasma levels
(P  .53, P  .01), but not with that of hs-CRP. Even
more important, in the CADPAD group, linear regres-
sion analyses showed that the transfemoral gradient of both
MPOx and IL-6 were the only variables significantly asso-
ciated with coronary artery endothelial function after ad-
justment for age, gender, and risk factors ( coefficient
0.53, 95% confidence interval [CI] 1.48-14.66, P .01 for
MPOx and  coefficient0.36, 95% CI11.73-0.91, P
.01 for IL-6). There was no relationship between coronary
artery endothelial function and the transcoronary gradient
of MPOx, IL-6, and hs-CRP.
Coronary artery endothelial function was not related to
inflammatory parameters in the CAD-only group. The
percentage increase in luminal diameter after nitroglycerin
was similar in the two groups.
Peripheral vascular inflammation and number of
significant coronary artery stenoses. The number of cor-
onary artery stenoses 50% was greater in CADPAD
patients with transfemoral gradients of MPOx  median
(median 4.0 [range 3.5 to 4.5]) vs both CADPAD pa-
tients with less peripheral vascular inflammation (median
2.5 [range 1.0 to 3.0]) (P  .01) and CAD-alone patients
(median 2.0 [range 1.0 to 4.0]) (P  .01) (P for trend 
.05) (Fig 2). The corresponding values for IL-6 were 4.0
(range 2.0 to 4.0); 3.0 (range 1.0 to 4.0); 2.0 (range 1.0 to
4.0) (Fig 3), thus showing a trend similar to that observed
for MPOx. However, at Kruskal-Wallis test, differences did
althy
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Noteworthy, an increased transfemoral gradient of MPOx
remained significantly associated with a higher number of
coronary stenoses after adjustment for classic risk factors (
coefficient 0.53, 95% CI 0.65-2.56; P  .05).
Peripheral vascular inflammation and prevalence of
three-vessel CAD. As shown in Fig 2, even the prevalence
of three-vessel CAD was greater in CADPAD patients
with transfemoral neutrophil activation (17/24; 71%) than
in the other two groups (6/22 [27%] in patients with lower
neutrophil activation [P .01], and 11/31 [35%] in those
with CAD-alone [P .05]). For IL-6 there was a progres-
sive increase in the prevalence of three-vessel CAD from
patients with CAD-alone (11/31, 35%) CADPAD pa-
Table II. Inflammatory markers measured in four vascular
Aorta Coronary sin
CAD 1.8 (5.6; 0.2) 1.1 (1.9
CADPAD 2.7 (4.8; 1.4) 2.2 (4.5
P
CAD 1.5 (0.9; 1.7) 1.3 (0.9;
CADPAD 1.4 (0.9; 3.1) 1.60 (1.1;
Pl
CAD 1.1 (0.4; 1.9) 0.5 (0.4;
CADPAD 2.3 (1.1; 5.8) 2.3 (1.1;
CAD, Coronary artery disease; PAD, peripheral arterial disease; MPOx, neu
protein.
*Significantly greater than in aorta (P  .01).
Fig 1. Venous-arterial differences in neutrophil myelo
(B) across femoral, coronary, and upper limb vascular
percentiles (boxes), and 10th and 90th percentiles (bars
(CADPAD) group, the differences in MPOx content a
significantly greater than that across the coronary circu
greater than that across the femoral circulation of the hetients with transfemoral gradient of IL-6  median (10/23, 43%) to CADPAD patients with IL-6 transfemoral
gradientmedian (13/23, 57%) (Fig 3). However, group
difference was not statistically significant (P for trend 
.32). At multivariate analysis, the transfemoral gradient of
MPOx resulted independently associated with the presence
of three-vessel CAD (odds ratio [OR] 12.2, 95% CI 1.8-
83.2; P  .01).
Peripheral vascular inflammation and prevalence of
MI. Previous MI was documented in 17 of 24 (71%)
patients who had an MPOx gradient across the femoral
circulation of the affected limb  median vs only 8/22
(36%) of those with lower transfemoral neutrophil activa-
tion, and 12/36 (39%) patients with CAD-alone (P for
trend .05) (Fig 2). Also patients with transfemoral IL-6
ricts
n Antecubital vein Femoral vein
MPOx index
) 2.1 (5.4; 0.4) 1.9 (6.6; 0.65)
) 3.4 (5.4; 0.4) 4.3 (7.2; 1.0)*
levels of IL-6 (pg/mL)
1.5 (1.1; 1.7) 1.4 (1.0; 1.7)
1.52 (0.8; 3.1) 1.7 (1.0; 3.1)*
levels of hs-CRP (mg/L)
1.0 (0.3; 1.9) 1.1 (0.5; 1.9)
2.5 (1.3; 5.6) 2.1 (1.3; 5.4)
il myeloperoxidase; IL-6, interleukin-6; hs-CRP, high sensitivity C-reactive
xidase (MPOx) content (A) and interleukin-6 (IL-6)
. Data are expressed as medians, with 25th and 75th
the coronary artery disease  peripheral arterial disease
-6 across the femoral circulation of the affected leg were
and the circulation of the upper limb. They were also
leg of CAD patients without PAD.dist
us vei
; 1.5
; 1.3
lasma
1.8)
2.6)
asma
1.5)
5.1)
trophpero
beds
). In
nd IL
lationgradient  median presented a prevalence of previous MI
ocard
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in both). However, no significant difference was observed
at Kruskal-Wallis analysis (P for trend  .25) (Fig 3).
Adjusted multivariate analysis showed that patients with
transfemoral V-A difference in MPOx  median had
roughly a sixfold increased risk of previous MI (OR 5.68,
95% CI 1.15-27.92; P  .05).
There was no relationship between the transfemoral
V-A differences in hs-CRP and CAD severity.
DISCUSSION
The present study confirms and extends the previous
finding that in CADPAD increased gradients of neutro-
phil MPOx content and IL-6 across the femoral circulation
of the affected limb are associated with impairment of the
coronary arteries.8 Actually, consistent with the previous
report, we found that the transfemoral differences of the
two inflammatory markers are strictly related to coronary
artery endothelial function. The novel finding of the
present report is that when an inflammatory response oc-
curs in the claudicant limb, it is associated with a more
Fig 2. Coronary artery disease (CAD) severity in CAD-
arterial disease (CADPAD) patients divided according
oxidase (MPOx) content. Data concerning continuous
number of significant coronary artery stenoses) are expre
categorical variables (three-vessel CAD and previous mysevere coronary atherosclerosis as evidenced by (1) a greaternumber of coronary stenoses; (2) a higher prevalence of
three-vessel CAD; and (3) a higher rate of previous MI.
Peripheral vascular inflammation. The increased
transfemoral gradients of neutrophil MPOx content and
IL-6 observed in the affected limb of CADPAD patients
was unlikely due to PAD-induced chronic ischemia or
impaired shear stress, because the extent of local inflamma-
tion did not correlate with ABI, which is a marker of
severity of circulatory insufficiency. Consequently, it is
conceivable that the local inflammatory response may be
related to the presence of active, inflamed plaques, which
are common in femoral arteries.10,11
The fact that CRP concentration in the blood leaving
the affected limb was similar to that observed in the other
vascular districts is consistent with a recent study on coro-
nary circulation,12 and excludes a transfemoral release of
this molecule. This suggests that MPOx and IL-6 are more
informative than plasma levels of CRP to disclose an inflam-
matory status in the arterial vessels of the claudicant limb.
Peripheral vascular inflammation and coronary artery
endothelial function. Neutrophil activation exerts impor-
patients, and in the coronary artery disease peripheral
median value of the transfemoral neutrophil myeloper-
bles (coronary artery endothelial function [CAEF] and
as median (10th, 25th, 75th, and 90th percentile) while
ial infarction [MI]) as number of patients (%).alone
to the
varia
ssedtant pathogenetic activities.13 In particular, MPOx released
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neutrophil content of the enzyme, uses nitric oxide as a
physiologic substrate, thereby reducing nitric oxide bio-
availability.14 Indeed, serum MPOx levels in humans in-
versely correlate with brachial artery flow-mediated vasodi-
lation.15 This, however, reflects a relationship between two
systemic measures. Therefore, more indicative of a mecha-
nistic link between inflammation and endothelial dysfunc-
tion are the results of the present study showing that a
regional non coronary inflammation is associated with a
coronary impairment of endothelial function. Indeed, in
CADPAD patients, the greater the venous arterial differ-
ence in neutrophil MPOx content across the femoral circu-
lation of the affected limb (and, thus, presumably the
greater the release of MPOx from activated neutrophils),
the more severe the endothelial dysfunction in the coronary
bed.8 Also, IL-6 may affect the endothelium,16 and we
found that the transfemoral difference in plasma levels of
IL-6 negatively correlated with coronary artery endothelial
function.
Noteworthy, coronary vasoreactivity was not related to
Fig 3. Coronary artery disease (CAD) severity in CAD-
arterial disease (CADPAD) patients divided accordin
interleukin-6 (IL-6) plasma levels across the femoral ci
variables (coronary artery endothelial function [CAEF
expressed as median (10th, 25th, 75th, and 90th percent
myocardial infarction [MI]) as number of patients (%).transcoronary gradient of inflammatory markers, thus ex-cluding that intracoronary vascular inflammation affected
coronary artery endothelial function.
Peripheral vascular inflammation and coronary ar-
tery atherosclerosis. That in CAD a concomitant PAD
entails a more severe coronary artery disease has been
widely report.5-7 Our data, although the cross-sectional
nature of this study does not allow us to draw a definitive
conclusion about causality, suggest the hypothesis that
peripheral vascular inflammation may play a pathoge-
netic role in CAD. Indeed, we found that CADPAD
patients with a transfemoral gradient in neutrophil MPOx
contentmedian had a higher number of coronary steno-
ses and a greater prevalence of three-vessel CAD than those
with lower transfemoral neutrophil activation and those
with CAD-alone. Furthermore, logistic regression analyses
showed that MPOx gradient across the affected femoral
circulation remained associated with worse coronary ath-
erosclerosis after adjustment for possible confounders.
These findings are in line with previous studies showing
that increased systemic levels of MPOx are associated with
a high number of coronary stenoses  50%17 and are
patients, and in the coronary artery disease peripheral
the median value of the venous-arterial difference in
tion of the affected limb. Data concerning continuous
number of significant coronary artery stenoses) are
hile categorical variables (three-vessel CAD and previousalone
g to
rcula
] and
ile) wrelated to CAD severity.9
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median tended to have a greater prevalence of three-vessel
CAD and/or of number of coronary stenoses  50% than
the other two groups, but the difference did not reach the
statistical significance. This could be the consequence of
the relative small size of our cohort. Indeed, in a previous
paper5 involving 234 patients who underwent coronary
angiography, increased levels of IL-6 appeared to be a
marker of more severe coronary atherosclerosis.
Peripheral vascular inflammation and prevalence of
MI. Another relevant finding of our study is that CAD
PAD patients with a transfemoral gradient in neutrophil
MPOx contentmedian had amarkedly higher prevalence
of MI than both those with a lower neutrophil activation
across the circulation of the affected limb, and CAD-alone
patients. A higher prevalence of MI was observed also in
patients with increased release of IL-6 from the affected
limb.
CONCLUSION
The conclusions that may be drawn from this hypothesis-
generating study are the following: first, in PAD the blood
leaving the inflamed claudicant limb contains molecules
that may affect coronary arteries. Therefore, PAD, besides
being a marker of cardiovascular risk, could have a mecha-
nistic role in the progression of atherosclerosis in coronary
arteries. Second, the fact that in CAD the coexistence of
PAD is associated with a more severe coronary atheroscle-
rosis may not be generalized to the entire population.
Actually, only patients with a marked inflammatory status
of the affected limb present a more severe coronary artery
endothelial function, a higher number of significant coro-
nary stenoses, a greater prevalence of three-vessel CAD,
and previous MI. Although the conclusions suggested by
our findings are intriguing, large prospective and possibly
non invasive study are required to confirm that the presence
of unstable inflamed plaques in the leg arteries portend a
worse outcome in PAD.
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